[{"id":"380a8863-daf3-4902-8a99-7907296c65b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03234712","created_at":"2021-01-18T15:59:05.637Z","updated_at":"2024-07-02T16:36:30.644Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)","source_id_and_acronym":"NCT03234712","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e serclutamab talirine (ABBV-321)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/10/2017","start_date":" 10/10/2017","primary_txt":" Primary completion: 04/14/2021","primary_completion_date":" 04/14/2021","study_txt":" Completion: 04/14/2021","study_completion_date":" 04/14/2021","last_update_posted":"2021-05-06"}]